Results 221 to 230 of about 82,478 (265)

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, Volume 13, Issue 35, 24 June 2026.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Mechanisms of Pericyte‐Mediated Cancer Metastasis

Advanced Science, Volume 13, Issue 33, 15 June 2026.
Pericytes play multifarious roles in promoting cancer metastasis by facilitating metastatic cancer cell dissemination, circulating tumor cell survival, tissue extravasation, premetastatic niche formation, and metastatic tumor growth. These cells have intertwined interactions with vascular endothelial cells to modulate cancer cell behavior and ...
Ziheng Guo, Yihai Cao
wiley   +1 more source

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

Advanced Science, Volume 13, Issue 35, 24 June 2026.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs, Pranay Nath, Alice Chen, Rizwan Romee, Andreia Maia   +4 more
wiley   +1 more source

Advances in Cancer Immunotherapy for Solid Tumors

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz, Harriet M. Kluger   +1 more
wiley   +1 more source

The soluble PD-L1 concentration is proportional to the expression of PD-L1 in tissue and is associated with a poor prognosis in human esophageal squamous cell carcinoma

, 2020
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients

Gastric Cancer, 2023
In this study, we compared programmed death-ligand 1 (PD-L1) expression in primary tissue samples and its soluble form (sPD-L1) concentration in matched preoperative plasma samples from gastric cancer patients to understand the relationship between tissue and plasma PD-L1 expression and to determine its diagnostic and prognostic value.PD-L1 expression ...
Mihaela Chivu-Economescu, Vlad Herlea, Simona Dima, Andrei Sorop, Catalin Pechianu, Alexandru Procop, Shuji Kitahara, Laura Necula, Lilia Matei, Denisa Dragu, Ana-Iulia Neagu, Coralia Bleotu, Carmen C. Diaconu, Irinel Popescu, Dan G. Duda   +14 more
openaire   +3 more sources

PD-L1 splice variant-driven soluble PD-L1 secretion promotes immune evasion in gastric cancer

International Journal of Biological Macromolecules
Soluble PD-L1 (sPD-L1) is implicated in tumor immunosuppression, but its cellular origins and clinical significance in gastric cancer (GC) remain unclear. This study aims to investigate the role of PD-L1 splice variants in generating sPD-L1 and evaluates its clinical significance and impact on immune evasion in GC. We measured serum sPD-L1 levels in GC
Kecheng, Jiang, Cheng, Chen, Shanshan, Yu, Jinxiao, Liang, Donghui, Zhou   +4 more
openaire   +3 more sources

The clinical significance of soluble PD-1 and PD-L1 in lung cancer

Critical Reviews in Oncology/Hematology, 2019
Soluble PD-1 and PD-L1 are detected in the serum and plasma of lung cancer patients. The significance of these soluble proteins as prognostic or predictive markers in lung cancer is uncertain. The testing methods used to detect soluble PD1/PD-L1 are variable with no agreement on a common definition of a positive test.
Taher Abu Hejleh, Muhammad Furqan, Zuhair K Ballas   +2 more
exaly   +3 more sources

Serum‐soluble PD‐L1 may be a potential diagnostic biomarker in sepsis

Scandinavian Journal of Immunology, 2021
AbstractTo investigate whether serum‐soluble PD‐L1 (sPD‐L1) is a potential biomarker for identifying sepsis. This study enrolled 64 septic patients, 29 patients with acute appendicitis, 33 patients with acute pancreatitis and 30 healthy volunteers.
Shaoqiong Sun, Yang Chen, Zhaojun Liu, Rui Tian, Jialin Liu, Erzhen Chen, Enqiang Mao, Tingting Pan, Hongping Qu   +8 more
openaire   +3 more sources

Soluble PD-L1 as a Predictive Biomarker in Lung Cancer: A Systematic Review and Meta-Analysis

Future Oncology, 2021
Background: We performed a meta-analysis to evaluate the association between soluble PD-L1 (sPD-L1) and survival outcomes and treatment response in lung cancer. Methods & methods: Eligible studies were obtained by searching PubMed, EMBASE and Web of Science.
Yang Cheng, Chong Wang, Yan Wang, Li Dai
openaire   +3 more sources